3 Dividend Stocks Built for Retirement to Buy in June

Quick Read

• VZ’s 6% yield is backed by $21.5 billion in projected free cash flow, while CVX has raised its dividend for 39 straight years.

• AbbVie’s Skyrizi surged 31% YoY, helping push Q1 revenue to $15 billion and prompting management to raise full-year EPS guidance.

• Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today.

Mid-year is when income-focused investors tend to take a hard look at their portfolios. With the second half of 2026 ahead, retirees and near-retirees are leaning into reliable dividend payers that can keep checks coming through any summer volatility. The three names below combine long dividend histories, defensive cash flows, and recent raises, exactly the profile that holds up when growth stocks wobble.

Verizon (NYSE: VZ)

Verizon (NYSE:VZ) is the high-yield anchor of this list. The stock trades at $46.95 with a trailing P/E of just 11 and a dividend yield around 6%, well above the broader market. The Q2 2026 payout was raised to $0.7075 per share, up from $0.69 the prior quarter, extending one of the longest uninterrupted dividend streaks in U.S. telecom.

The bull case is straightforward for retirees. Q1 2026 adjusted EPS came in at $1.28, up 8% YoY, and management raised full-year guidance to $4.95 to $4.99 in adjusted EPS with free cash flow of at least $21.5 billion, which more than covers the dividend. The closed Frontier Communications acquisition pushed fiber broadband connections up 42% YoY to roughly 10.8 million, and Verizon posted its first positive Q1 postpaid phone net adds since 2013. CEO Dan Schulman summed it up: “Our turnaround is not only progressing, it is gaining momentum.” Shares are up 16% year to date, yet still trade below the analyst target of $51.85.

Risk to watch: Total debt climbed to $172.5 billion after the Frontier deal, interest expense rose 19% YoY, and postpaid phone churn ticked up to 1%. Leverage will dictate how quickly future raises arrive.

Chevron (NYSE: CVX)

Chevron (NYSE:CVX) is the dividend aristocrat of the group. The Q1 2026 dividend was raised to $1.78 per share quarterly, marking the 39th consecutive annual increase. That payment landed in shareholder accounts on June 10, 2026, the same day this article runs. Shares closed at $186.76 on June 9 and have risen 25% year to date, yet the forward P/E sits at a reasonable 14.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today.

The retirement thesis here is fortress cash returns. Chevron posted Q1 2026 adjusted EPS of $1.41 versus $0.97 estimates, its sixth consecutive quarterly EPS beat. Worldwide production rose 15% YoY to 3,858 MBOED, with the Permian Basin now at 1 million BOE/day following Hess integration. Chevron has returned cash on autopilot, posting 16 consecutive quarters returning more than $5 billion to shareholders, including $2.5 billion in Q1 buybacks. CEO Mike Wirth pointed to “the resilience of our portfolio and the value of disciplined execution.”

Risk to watch: Q1 net income fell 37% YoY, free cash flow turned negative at -$1.55 billion on working capital swings, and the net debt ratio crept to 18%. Oil-price sensitivity and Middle East exposure remain the obvious wildcards.

AbbVie (NYSE: ABBV)

AbbVie (NYSE:ABBV) rounds out the trio as the healthcare leg. The stock closed at $225.42 on June 9 with a dividend yield near 3% and a forward P/E of 16. The dividend was raised to $1.73 per quarter in 2026, up from $1.64, continuing a march from just $0.40 per quarter in 2013.

The plain-language bull case: the post-Humira transition is going faster than skeptics expected. Q1 2026 revenue hit $15.00 billion, up 12% YoY, beating the $14.72 billion estimate. Skyrizi grew 31% YoY to $4.48 billion, Rinvoq added 23%, and neuroscience expanded 26%. Management raised 2026 adjusted EPS guidance to $14.08 to $14.28. CEO Robert A. Michael said the company is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.” Analysts carry an average target of $253.55.

Risk to watch: Humira sales fell 39% to $688 million as biosimilars bite, Imbruvica dropped 25%, and GAAP earnings remain weighed down by acquired IPR&D charges. Investors will want to see Skyrizi and Rinvoq continue carrying the load past 2028.

What to Watch Next

All three names share the traits retirement portfolios tend to prize: long dividend histories, recent raises, defensive end markets, and forward P/E ratios in the low-to-mid teens. Verizon offers the deepest yield, Chevron the longest aristocrat streak, and AbbVie the best growth profile of the group. Keep an eye on Q2 earnings reports later this summer, when each management team will update guidance heading into the second half.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today.